论文部分内容阅读
许多科学家曾试图在体外免疫人B细胞制备所需的特异性单克隆抗体(McAb),但他们的试验都遭到失败。最近瑞典隆德大学的Borrebaeck等获得了成功。 Borrebaeck把过去试验失败的原因归咎于试验所用细胞中含有部分富含溶酶体的淋巴细胞。Borrebaeck等用亲溶酶体亮氨酸甲酯处理人周围血淋巴细胞,去除富含溶酶体细胞,剩余的细胞体外免疫获得成功。培养基中必需加入白细胞介素2、γ干扰素及B细胞生长和分化因子。
Many scientists have tried to immunize human B cells in vitro to produce the desired monoclonal antibodies (McAbs), but their experiments have failed. The recent success of Borrebaeck, Lund University in Sweden, among others. Borrebaeck attributed the failure of the past trial to the fact that some of the cells used in the experiment contained some lysosome-rich lymphocytes. Borrebaeck et al treated human peripheral blood lymphocytes with lysosomal leucine to remove lysosome-rich cells, and the remaining cells were successfully immunized in vitro. Necessary to join the medium of interleukin 2, γ interferon and B cell growth and differentiation factor.